Analytical Overview: BioXcel Therapeutics Inc (BTAI)’s Ratios Tell a Financial Story

Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

As of close of business last night, BioXcel Therapeutics Inc’s stock clocked out at $1.81, up 1.69% from its previous closing price of $1.78. In other words, the price has increased by $1.69 from its previous closing price. On the day, 1.83 million shares were traded. BTAI stock price reached its highest trading level at $1.93 during the session, while it also had its lowest trading level at $1.74.


To gain a deeper understanding of BTAI’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.49 and its Current Ratio is at 2.57.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, UBS on February 21, 2024, Downgraded its rating to Neutral and sets its target price to $4 from $9 previously.

On August 15, 2023, Mizuho Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $40 to $4.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 04 ’24 when Mehta Vimal sold 5,268 shares for $2.62 per share. The transaction valued at 13,823 led to the insider holds 43,564 shares of the business.

Steinhart Richard I sold 1,069 shares of BTAI for $2,817 on Apr 04 ’24. The Chief Financial Officer now owns 4,765 shares after completing the transaction at $2.63 per share. On Apr 04 ’24, another insider, Yocca Frank, who serves as the Chief Scientific Officer of the company, sold 1,067 shares for $2.63 each. As a result, the insider received 2,812 and left with 12,763 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BTAI now has a Market Capitalization of 67930744 and an Enterprise Value of 96125784. For the stock, the TTM Price-to-Sale (P/S) ratio is 38.60. Its current Enterprise Value per Revenue stands at 54.741 whereas that against EBITDA is -0.685.

Stock Price History:

Over the past 52 weeks, BTAI has reached a high of $22.06, while it has fallen to a 52-week low of $1.77. The 50-Day Moving Average of the stock is -26.89%, while the 200-Day Moving Average is calculated to be -41.70%.

Shares Statistics:

It appears that BTAI traded 539.18K shares on average per day over the past three months and 713450 shares per day over the past ten days. A total of 29.93M shares are outstanding, with a floating share count of 28.34M. Insiders hold about 24.48% of the company’s shares, while institutions hold 24.92% stake in the company. Shares short for BTAI as of 1715731200 were 1631200 with a Short Ratio of 3.03, compared to 1713139200 on 2087650. Therefore, it implies a Short% of Shares Outstanding of 1631200 and a Short% of Float of 5.7299999999999995.

Most Popular